Completed OBSERVATIONAL NCT00167973

Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

A Prospective Registry of European Hemophilia B Patients Receiving BeneFIX®(Nonacog Alfa, Recombinant Human Factor IX) for Usual Use

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Hemophilia B

Updated 7 times since 2017 Last updated: May 25, 2010 Started: Jan 31, 2002 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hemophilia B and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almería, Spain , Amiens, France , Amsterdam, Netherlands , Ancona, Italy , Angers, France , Barcelona, Spain , Bari, Italy , Birmingham, United Kingdom , Breda, Netherlands , Brussels, Belgium and 69 more locations